You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameNaltrexone
Accession NumberDB00704  (APRD00005, DB05067)
TypeSmall Molecule
GroupsApproved, Investigational, Vet Approved
DescriptionDerivative of noroxymorphone that is the N-cyclopropylmethyl congener of naloxone. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence. [PubChem]
Structure
Thumb
Synonyms
17-(Cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxymorphinan-6-one
17-(Cyclopropylmethyl)-4,5alpha-epoxy-3,14-dihydroxymorphinan-6-one
N-Cyclopropylmethyl-14-hydroxydihydromorphinone
N-Cyclopropylmethylnoroxymorphone
Naltrexon
Naltrexona
Naltrexone
Naltrexonum
External IDs EN-1639 A / UM 792
Product Ingredients
IngredientUNIICASInChI KeyDetails
Naltrexone HydrochlorideNot AvailableNot AvailableRHBRMCOKKKZVRY-ITLPAZOVSA-NDetails
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Naltrexone Hydrochloride Tablets USPTablet50 mgOralSterinova IncNot applicableNot applicableCanada
ReviaTablet50 mgOralTeva1997-10-23Not applicableCanada
Revia - Tab 50mgTablet50 mgOralDupont Merck Pharma Inc.1995-12-311998-08-13Canada
VivitrolKitAlkermes, Inc.2006-06-13Not applicableUs
VivitrolKitAlkermes, Inc.2006-06-132016-02-13Us
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-naltrexoneTablet50 mgOralApotex Corporation2015-11-10Not applicableCanada
Naltrexone HydrochlorideTablet, film coated50 mg/1OralPd Rx Pharmaceuticals, Inc.1998-05-08Not applicableUs
Naltrexone HydrochlorideTablet, film coated50 mg/1Oralbryant ranch prepack1998-05-08Not applicableUs
Naltrexone HydrochlorideTablet, film coated50 mg/1OralAccord Healthcare Limited2011-10-01Not applicableUs
Naltrexone HydrochlorideTablet, film coated50 mg/1OralPd Rx Pharmaceuticals, Inc.2009-07-29Not applicableUs
Naltrexone HydrochlorideTablet, film coated50 mg/1OralAmerincan Health Packaging2012-01-02Not applicableUs
Naltrexone HydrochlorideTablet, film coated50 mg/1OralNu Care Pharmaceuticls, Inc.2013-09-23Not applicableUs
Naltrexone HydrochlorideTablet, film coated50 mg/1OralSun Pharma Global FZE2012-02-29Not applicableUs
Naltrexone HydrochlorideTablet, film coated50 mg/1OralPrecision Dose, Inc.2014-10-29Not applicableUs
Naltrexone HydrochlorideTablet, film coated50 mg/1OralA S Medication Solutions2013-09-23Not applicableUs
Naltrexone HydrochlorideTablet, film coated50 mg/1OralTAGI Pharma, Inc.2013-09-23Not applicableUs
Naltrexone HydrochlorideTablet, film coated50 mg/1OralAidarex Pharmaceuticals LLC2013-09-23Not applicableUs
Naltrexone HydrochlorideTablet, film coated50 mg/1OralBarr Laboratories1998-05-08Not applicableUs
Naltrexone HydrochlorideTablet, film coated50 mg/1OralRemedy Repack2013-10-072016-12-29Us
Naltrexone HydrochlorideTablet, film coated50 mg/1OralMallinckrodt2009-07-29Not applicableUs
Naltrexone HydrochlorideTablet, film coated50 mg/1OralAvera Mc Kennan Hospital2016-02-10Not applicableUs
Naltrexone HydrochlorideTablet, film coated50 mg/1OralAv Kare, Inc.2015-03-26Not applicableUs
Naltrexone HydrochlorideTablet, film coated50 mg/1OralPhysicians Total Care, Inc.2006-04-19Not applicableUs
Naltrexone HydrochlorideTablet, film coated50 mg/1OralUnit Dose Services1998-05-082017-08-31Us
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AbernilMedochemie
AdependAOP Orphan
AntaxonZambon
AntaxonePharmazam
ArropQuimico
CelupanNot Available
DepadeNot Available
DependexAmomed
MorVivaNot Available
NaleronaABL Pharma
NalorexBristol-Myers Squibb
NaltaxNavana
NaltreksonWyeth
NarcoralSirton
NeksiGMP
NemexinBristol-Myers Squibb
OpizoneBritannia
RevezSoubeiran Chobet
TrexanDu Pont
VivitrexNot Available
Brand mixtures
NameLabellerIngredients
ContraveTakeda
Contrave Extended-releaseOrexigen Therapeutics, Inc.
EmbedaStat Rx USA
Troxyca ERPfizer Laboratories Div Pfizer Inc.
Categories
UNII5S6W795CQM
CAS number16590-41-3
WeightAverage: 341.4009
Monoisotopic: 341.162708229
Chemical FormulaC20H23NO4
InChI KeyDQCKKXVULJGBQN-XFWGSAIBSA-N
InChI
InChI=1S/C20H23NO4/c22-13-4-3-12-9-15-20(24)6-5-14(23)18-19(20,16(12)17(13)25-18)7-8-21(15)10-11-1-2-11/h3-4,11,15,18,22,24H,1-2,5-10H2/t15-,18+,19+,20-/m1/s1
IUPAC Name
(1S,5R,13R,17S)-4-(cyclopropylmethyl)-10,17-dihydroxy-12-oxa-4-azapentacyclo[9.6.1.0¹,¹³.0⁵,¹⁷.0⁷,¹⁸]octadeca-7(18),8,10-trien-14-one
SMILES
[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(CC3CC3)[C@]([H])(C4)[C@]1(O)CCC2=O
Pharmacology
IndicationUsed as an adjunct to a medically supervised behaviour modification program in the maintenance of opiate cessation in individuals who were formerly physically dependent on opiates and who have successfully undergone detoxification. Also used for the management of alcohol dependence in conjunction with a behavioural modification program.
Structured Indications
PharmacodynamicsNaltrexone, a pure opioid antagonist, is a synthetic congener of oxymorphone with no opioid agonist properties. Naltrexone is indicated in the treatment of alcohol dependence and for the blockade of the effects of exogenously administered opioids. It markedly attenuates or completely blocks, reversibly, the subjective effects of intravenously administered opioids. When co-administered with morphine, on a chronic basis, naltrexone blocks the physical dependence to morphine, heroin and other opioids. In subjects physically dependent on opioids, naltrexone will precipitate withdrawal symptomatology.
Mechanism of actionNaltrexone is a pure opiate antagonist and has little or no agonist activity. The mechanism of action of naltrexone in alcoholism is not understood; however, involvement of the endogenous opioid system is suggested by preclinical data. Naltrexone is thought to act as a competitive antagonist at mc, κ, and δ receptors in the CNS, with the highest affintiy for the μ receptor. Naltrexone competitively binds to such receptors and may block the effects of endogenous opioids. This leads to the antagonization of most of the subjective and objective effects of opiates, including respiratory depression, miosis, euphoria, and drug craving. The major metabolite of naltrexone, 6-β-naltrexol, is also an opiate antagonist and may contribute to the antagonistic activity of the drug.
TargetKindPharmacological actionActionsOrganismUniProt ID
Mu-type opioid receptorProteinyes
antagonist
HumanP35372 details
Kappa-type opioid receptorProteinyes
antagonist
HumanP41145 details
Delta-type opioid receptorProteinyes
antagonist
HumanP41143 details
HCG20471, isoform CRA_cProteinyes
antagonist
HumanQ5T1J1 details
Related Articles
AbsorptionAlthough well absorbed orally, naltrexone is subject to significant first pass metabolism with oral bioavailability estimates ranging from 5 to 40%.
Volume of distribution
  • 1350 L [intravenous administration]
Protein binding21% bound to plasma proteins over the therapeutic dose range.
Metabolism

Hepatic. When administered orally, naltrexone undergoes extensive biotransformation and is metabolized to 6 beta-naltrexol (which may contribute to the therapeutic effect) and other minor metabolites.

SubstrateEnzymesProduct
Naltrexone
Not Available
6-beta-naltrexolDetails
Route of eliminationBoth parent drug and metabolites are excreted primarily by the kidney (53% to 79% of the dose), however, urinary excretion of unchanged naltrexone accounts for less than 2% of an oral dose and fecal excretion is a minor elimination pathway. The renal clearance for naltrexone ranges from 30 to 127 mL/min and suggests that renal elimination is primarily by glomerular filtration.
Half life4 hours for naltrexone and 13 hours for the active metabolite 6 beta-naltrexol.
Clearance
  • ~ 3.5 L/min [after IV administration]
ToxicityIn the mouse, rat and guinea pig, the oral LD50s were 1,100-1,550 mg/kg; 1,450 mg/kg; and 1,490 mg/kg; respectively. High doses of naltrexone (generally ≥1,000 mg/kg) produce salivation, depression/reduced activity, tremors, and convulsions.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Naltrexone Action PathwayDrug actionSMP00687
Pharmacogenomic Effects/ADRs
Interacting Gene/EnzymeAllele nameGenotype(s)Defining Change(s)Type(s)DescriptionDetails
Mu-type opioid receptor---(G;G) / (A;G)A > G Effect Directly StudiedThose with the AG genotype respond better to therapy (increase number of abstinent days) Details
Interactions
Drug Interactions
DrugInteractionDrug group
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Naltrexone.Approved
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Naltrexone.Approved
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Naltrexone.Approved, Vet Approved
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Naltrexone.Approved
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Naltrexone.Experimental
AlfentanilThe therapeutic efficacy of Alfentanil can be decreased when used in combination with Naltrexone.Approved, Illicit
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Naltrexone.Approved, Investigational
AlphacetylmethadolThe therapeutic efficacy of Alphacetylmethadol can be decreased when used in combination with Naltrexone.Experimental, Illicit
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Naltrexone.Approved, Investigational
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Naltrexone.Approved
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Naltrexone.Approved
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Naltrexone.Approved, Investigational
AtazanavirThe serum concentration of Atazanavir can be increased when it is combined with Naltrexone.Approved, Investigational
AtenololThe serum concentration of Atenolol can be increased when it is combined with Naltrexone.Approved
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Naltrexone.Approved, Investigational
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Naltrexone.Approved, Vet Approved
BezitramideThe therapeutic efficacy of Bezitramide can be decreased when used in combination with Naltrexone.Experimental, Illicit, Withdrawn
BoceprevirThe serum concentration of Boceprevir can be increased when it is combined with Naltrexone.Approved
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Naltrexone.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Naltrexone.Approved
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Naltrexone.Approved, Investigational
BuprenorphineThe therapeutic efficacy of Buprenorphine can be decreased when used in combination with Naltrexone.Approved, Illicit, Investigational, Vet Approved
ButorphanolThe therapeutic efficacy of Butorphanol can be decreased when used in combination with Naltrexone.Approved, Illicit, Vet Approved
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Naltrexone.Approved
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Naltrexone.Approved
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Naltrexone.Experimental
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Naltrexone.Approved
CarbamazepineThe serum concentration of Carbamazepine can be increased when it is combined with Naltrexone.Approved, Investigational
CarfentanilThe therapeutic efficacy of Carfentanil can be decreased when used in combination with Naltrexone.Illicit, Vet Approved
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Naltrexone.Approved
CeritinibThe serum concentration of Ceritinib can be increased when it is combined with Naltrexone.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Naltrexone.Withdrawn
ChlorpromazineThe serum concentration of Chlorpromazine can be increased when it is combined with Naltrexone.Approved, Vet Approved
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Naltrexone.Approved
CiprofloxacinThe serum concentration of Ciprofloxacin can be increased when it is combined with Naltrexone.Approved, Investigational
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Naltrexone.Approved
CitalopramThe serum concentration of Citalopram can be increased when it is combined with Naltrexone.Approved
ClarithromycinThe serum concentration of Clarithromycin can be increased when it is combined with Naltrexone.Approved
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Naltrexone.Approved, Illicit
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Naltrexone.Approved, Investigational
ClonidineThe serum concentration of Clonidine can be increased when it is combined with Naltrexone.Approved
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Naltrexone.Approved, Nutraceutical
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Naltrexone.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Naltrexone.Approved
CodeineThe therapeutic efficacy of Codeine can be decreased when used in combination with Naltrexone.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Naltrexone.Approved
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Naltrexone.Approved
CrizotinibThe serum concentration of Crizotinib can be increased when it is combined with Naltrexone.Approved
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Naltrexone.Approved, Investigational, Vet Approved
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Naltrexone.Approved
DabrafenibThe serum concentration of Dabrafenib can be increased when it is combined with Naltrexone.Approved
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Naltrexone.Approved
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Naltrexone.Approved
DasatinibThe serum concentration of Dasatinib can be increased when it is combined with Naltrexone.Approved, Investigational
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Naltrexone.Approved
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Naltrexone.Approved
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Naltrexone.Approved, Investigational, Vet Approved
DextromoramideThe therapeutic efficacy of Dextromoramide can be decreased when used in combination with Naltrexone.Experimental, Illicit
DextropropoxypheneThe therapeutic efficacy of Dextropropoxyphene can be decreased when used in combination with Naltrexone.Approved, Illicit, Withdrawn
DezocineThe therapeutic efficacy of Dezocine can be decreased when used in combination with Naltrexone.Approved
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Naltrexone.Approved, Illicit, Vet Approved
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Naltrexone.Approved
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Naltrexone.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Naltrexone.Approved
DihydrocodeineThe therapeutic efficacy of Dihydrocodeine can be decreased when used in combination with Naltrexone.Approved, Illicit
DihydroetorphineThe therapeutic efficacy of Dihydroetorphine can be decreased when used in combination with Naltrexone.Experimental, Illicit
DihydromorphineThe therapeutic efficacy of Dihydromorphine can be decreased when used in combination with Naltrexone.Experimental, Illicit
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Naltrexone.Illicit
DiltiazemThe serum concentration of Diltiazem can be increased when it is combined with Naltrexone.Approved
DiphenoxylateThe therapeutic efficacy of Diphenoxylate can be decreased when used in combination with Naltrexone.Approved, Illicit
DipyridamoleThe serum concentration of Dipyridamole can be increased when it is combined with Naltrexone.Approved
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Naltrexone.Approved, Investigational
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Naltrexone.Approved, Investigational, Vet Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Naltrexone.Approved, Investigational
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Naltrexone.Approved
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Naltrexone.Approved, Investigational
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Naltrexone.Approved, Investigational
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Naltrexone.Approved, Investigational
ErythromycinThe serum concentration of Erythromycin can be increased when it is combined with Naltrexone.Approved, Vet Approved
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Naltrexone.Approved, Investigational, Vet Approved
EstriolThe serum concentration of Estriol can be increased when it is combined with Naltrexone.Approved, Vet Approved
EstroneThe serum concentration of Estrone can be increased when it is combined with Naltrexone.Approved
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Naltrexone.Approved
EthylmorphineThe therapeutic efficacy of Ethylmorphine can be decreased when used in combination with Naltrexone.Approved, Illicit
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Naltrexone.Approved
EtorphineThe therapeutic efficacy of Etorphine can be decreased when used in combination with Naltrexone.Illicit, Vet Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Naltrexone.Approved
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Naltrexone.Approved
FentanylThe therapeutic efficacy of Fentanyl can be decreased when used in combination with Naltrexone.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of Fesoterodine can be increased when it is combined with Naltrexone.Approved
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Naltrexone.Approved
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Naltrexone.Approved
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Naltrexone.Approved
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Naltrexone.Approved, Investigational
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Naltrexone.Approved
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Naltrexone.Approved
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Naltrexone.Withdrawn
HaloperidolThe serum concentration of Haloperidol can be increased when it is combined with Naltrexone.Approved
HeroinThe therapeutic efficacy of Heroin can be decreased when used in combination with Naltrexone.Approved, Illicit
HydrocodoneThe therapeutic efficacy of Hydrocodone can be decreased when used in combination with Naltrexone.Approved, Illicit
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Naltrexone.Approved, Vet Approved
HydromorphoneThe therapeutic efficacy of Hydromorphone can be decreased when used in combination with Naltrexone.Approved, Illicit
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Naltrexone.Approved
IdelalisibThe serum concentration of Idelalisib can be increased when it is combined with Naltrexone.Approved
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Naltrexone.Approved
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Naltrexone.Approved
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Naltrexone.Approved
IndinavirThe serum concentration of Indinavir can be increased when it is combined with Naltrexone.Approved
IndomethacinThe serum concentration of Indomethacin can be increased when it is combined with Naltrexone.Approved, Investigational
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Naltrexone.Approved, Investigational
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Naltrexone.Approved, Vet Approved
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Naltrexone.Approved
KetobemidoneThe therapeutic efficacy of Ketobemidone can be decreased when used in combination with Naltrexone.Approved
KetoconazoleThe serum concentration of Ketoconazole can be increased when it is combined with Naltrexone.Approved, Investigational
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Naltrexone.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Naltrexone.Approved, Investigational
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Naltrexone.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Naltrexone.Approved
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Naltrexone.Approved
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Naltrexone.Approved
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Naltrexone.Approved, Investigational
LevofloxacinThe serum concentration of Levofloxacin can be increased when it is combined with Naltrexone.Approved, Investigational
Levomethadyl AcetateThe therapeutic efficacy of Levomethadyl Acetate can be decreased when used in combination with Naltrexone.Approved
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Naltrexone.Approved
LevorphanolThe therapeutic efficacy of Levorphanol can be decreased when used in combination with Naltrexone.Approved
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Naltrexone.Approved
LofentanilThe therapeutic efficacy of Lofentanil can be decreased when used in combination with Naltrexone.Illicit
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Naltrexone.Approved
LosartanThe serum concentration of Losartan can be increased when it is combined with Naltrexone.Approved
MannitolThe serum concentration of Mannitol can be increased when it is combined with Naltrexone.Approved, Investigational
MethadoneThe therapeutic efficacy of Methadone can be decreased when used in combination with Naltrexone.Approved
Methadyl AcetateThe therapeutic efficacy of Methadyl Acetate can be decreased when used in combination with Naltrexone.Approved, Illicit
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Naltrexone.Approved
MethylnaltrexoneThe risk or severity of adverse effects can be increased when Methylnaltrexone is combined with Naltrexone.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Naltrexone.Approved, Vet Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Naltrexone.Approved, Investigational
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Naltrexone.Approved, Illicit
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Naltrexone.Approved
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Naltrexone.Approved, Investigational
MorphineThe therapeutic efficacy of Morphine can be decreased when used in combination with Naltrexone.Approved, Investigational
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Naltrexone.Approved, Investigational
NadololThe serum concentration of Nadolol can be increased when it is combined with Naltrexone.Approved
NalbuphineThe therapeutic efficacy of Nalbuphine can be decreased when used in combination with Naltrexone.Approved
NaloxegolThe risk or severity of adverse effects can be increased when Naltrexone is combined with Naloxegol.Approved
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Naltrexone.Approved, Vet Approved
NelfinavirThe serum concentration of Nelfinavir can be increased when it is combined with Naltrexone.Approved
NicardipineThe serum concentration of Nicardipine can be increased when it is combined with Naltrexone.Approved
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Naltrexone.Approved
NilotinibThe serum concentration of Nilotinib can be increased when it is combined with Naltrexone.Approved, Investigational
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Naltrexone.Approved
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Naltrexone.Approved
NormethadoneThe therapeutic efficacy of Normethadone can be decreased when used in combination with Naltrexone.Approved, Illicit
OlanzapineThe serum concentration of Olanzapine can be increased when it is combined with Naltrexone.Approved, Investigational
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Naltrexone.Approved
OpiumThe therapeutic efficacy of Opium can be decreased when used in combination with Naltrexone.Approved, Illicit
OsimertinibThe serum concentration of Osimertinib can be increased when it is combined with Naltrexone.Approved
OxycodoneThe therapeutic efficacy of Oxycodone can be decreased when used in combination with Naltrexone.Approved, Illicit, Investigational
OxymorphoneThe therapeutic efficacy of Oxymorphone can be decreased when used in combination with Naltrexone.Approved, Investigational, Vet Approved
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Naltrexone.Approved, Vet Approved
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Naltrexone.Approved, Investigational
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Naltrexone.Approved
PentazocineThe therapeutic efficacy of Pentazocine can be decreased when used in combination with Naltrexone.Approved, Vet Approved
PethidineThe therapeutic efficacy of Pethidine can be decreased when used in combination with Naltrexone.Approved
PhenobarbitalThe serum concentration of Phenobarbital can be increased when it is combined with Naltrexone.Approved
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Naltrexone.Approved, Vet Approved
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Naltrexone.Approved
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Naltrexone.Approved
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Naltrexone.Approved
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Naltrexone.Approved
PrazosinThe serum concentration of Prazosin can be increased when it is combined with Naltrexone.Approved
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Naltrexone.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Naltrexone.Approved, Vet Approved
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Naltrexone.Approved, Vet Approved
PropranololThe serum concentration of Propranolol can be increased when it is combined with Naltrexone.Approved, Investigational
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Naltrexone.Approved
QuetiapineThe serum concentration of Quetiapine can be increased when it is combined with Naltrexone.Approved
QuinidineThe serum concentration of Quinidine can be increased when it is combined with Naltrexone.Approved
QuinineThe serum concentration of Quinine can be increased when it is combined with Naltrexone.Approved
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Naltrexone.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Naltrexone.Approved, Investigational
RemifentanilThe therapeutic efficacy of Remifentanil can be decreased when used in combination with Naltrexone.Approved
ReserpineThe serum concentration of Reserpine can be increased when it is combined with Naltrexone.Approved
RifampicinThe serum concentration of Rifampicin can be increased when it is combined with Naltrexone.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Naltrexone.Approved, Investigational
RisperidoneThe serum concentration of Risperidone can be increased when it is combined with Naltrexone.Approved, Investigational
RitonavirThe serum concentration of Ritonavir can be increased when it is combined with Naltrexone.Approved, Investigational
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Naltrexone.Approved
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Naltrexone.Approved, Investigational
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Naltrexone.Approved, Vet Approved
SaquinavirThe serum concentration of Saquinavir can be increased when it is combined with Naltrexone.Approved, Investigational
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Naltrexone.Approved
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Naltrexone.Approved
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Naltrexone.Approved
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Naltrexone.Approved, Investigational
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Naltrexone.Approved
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Naltrexone.Approved, Investigational
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Naltrexone.Approved
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Naltrexone.Experimental
SufentanilThe therapeutic efficacy of Sufentanil can be decreased when used in combination with Naltrexone.Approved, Investigational
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Naltrexone.Approved, Investigational
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Naltrexone.Approved
TapentadolThe therapeutic efficacy of Tapentadol can be decreased when used in combination with Naltrexone.Approved
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Naltrexone.Experimental
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Naltrexone.Approved
TelaprevirThe serum concentration of Telaprevir can be increased when it is combined with Naltrexone.Approved
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Naltrexone.Approved
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Naltrexone.Approved
TimololThe serum concentration of Timolol can be increased when it is combined with Naltrexone.Approved
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Naltrexone.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Naltrexone.Approved, Investigational
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Naltrexone.Approved, Investigational
TramadolThe therapeutic efficacy of Tramadol can be decreased when used in combination with Naltrexone.Approved, Investigational
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Naltrexone.Approved
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Naltrexone.Approved
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Naltrexone.Approved
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Naltrexone.Approved
VenetoclaxThe serum concentration of Venetoclax can be increased when it is combined with Naltrexone.Approved
VenlafaxineThe serum concentration of Venlafaxine can be increased when it is combined with Naltrexone.Approved
VerapamilThe serum concentration of Verapamil can be increased when it is combined with Naltrexone.Approved
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Naltrexone.Approved
VincristineThe serum concentration of Vincristine can be increased when it is combined with Naltrexone.Approved, Investigational
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Naltrexone.Approved
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Naltrexone.Approved
Food Interactions
  • Take without regard to meals.
References
Synthesis Reference

Bao-Shan Huang, Yansong Lu, Ben-Yi Ji, Aris P Christodoulou, “Preparation of naltrexone from codeine and 3-benzylmorphine.” U.S. Patent US6013796, issued March, 1990.

US6013796
General References
  1. Schmitz JM, Stotts AL, Rhoades HM, Grabowski J: Naltrexone and relapse prevention treatment for cocaine-dependent patients. Addict Behav. 2001 Mar-Apr;26(2):167-80. [PubMed:11316375 ]
  2. Krystal JH, Gueorguieva R, Cramer J, Collins J, Rosenheck R: Naltrexone is associated with reduced drinking by alcohol dependent patients receiving antidepressants for mood and anxiety symptoms: results from VA Cooperative Study No. 425, "Naltrexone in the treatment of alcoholism". Alcohol Clin Exp Res. 2008 Jan;32(1):85-91. Epub 2007 Dec 7. [PubMed:18070245 ]
  3. Ray LA, Chin PF, Miotto K: Naltrexone for the treatment of alcoholism: clinical findings, mechanisms of action, and pharmacogenetics. CNS Neurol Disord Drug Targets. 2010 Mar;9(1):13-22. [PubMed:20201811 ]
External Links
ATC CodesA08AA62N07BB04
AHFS Codes
  • 28:10.00
PDB EntriesNot Available
FDA labelDownload (1.83 MB)
MSDSDownload (73.9 KB)
Clinical Trials
Clinical Trials
PhaseStatusPurposeConditionsCount
0CompletedTreatmentAlcohol Dependence / Alcoholism1
1CompletedNot AvailableHealthy Volunteers1
1CompletedNot AvailablePostoperative Pain1
1CompletedBasic ScienceAlcohol Dependence1
1CompletedBasic ScienceHealthy Volunteers3
1CompletedBasic ScienceNondependent Opioid Abuse, Episodic1
1CompletedDiagnosticMethamphetamine Dependence1
1CompletedSupportive CarePsychotic Disorders / Schizophrenia1
1CompletedTreatmentAlcoholism2
1CompletedTreatmentECG Effects1
1CompletedTreatmentHealthy Volunteers1
1CompletedTreatmentOpioid-Related Disorders1
1CompletedTreatmentPain1
1RecruitingTreatmentAlcohol Drinking1
1RecruitingTreatmentCutaneous Nerves CNS Itch1
1RecruitingTreatmentDepression1
1RecruitingTreatmentGambling1
1RecruitingTreatmentOpioid Dependence1
1RecruitingTreatmentOpioid Dependence / Opioid Use Disorders1
1, 2CompletedTreatmentAids / Drug Dependence / HIV Disease / Opioid Dependence1
1, 2CompletedTreatmentAlcohol Dependence / Bipolar Disorder (BD)1
1, 2CompletedTreatmentCannabis Dependence1
1, 2CompletedTreatmentHypoglycemia Unawareness / Type 1 Diabetes Mellitus (T1DM)1
1, 2CompletedTreatmentNicotine Dependence / Smoking2
1, 2CompletedTreatmentStable Opioid Dependence1
1, 2RecruitingTreatmentAlcohol Abuse / Alcohol Drinking / Alcohol Use Disorders (AUD) / Alcohol-Related Disorders / Alcoholism1
1, 2Unknown StatusTreatmentPervasive Developmental Disorders1
2Active Not RecruitingSupportive CareCarcinoma, Lobular / Ductal Carcinoma In Situ / Fatigue Related to Cancer Treatment / Invasive Breast Cancer (Stage I-III) / Lobular Carcinoma in Situ (LCIS)1
2Active Not RecruitingTreatmentHIV+1
2Active Not RecruitingTreatmentOpiate Dependence1
2Active Not RecruitingTreatmentOpioid Dependence1
2Active Not RecruitingTreatmentPathological Gambling1
2CompletedNot AvailableAlcoholism1
2CompletedNot AvailableTobacco Dependence1
2CompletedBasic ScienceMarijuana Dependence1
2CompletedBasic ScienceSmoking, Marijuana2
2CompletedPreventionAlcohols / Methamphetamine1
2CompletedPreventionHIV Seropositivity1
2CompletedPreventionOpiate Addiction1
2CompletedTreatmentAlcohol Abuse / Alcohol Dependence1
2CompletedTreatmentAlcohol Dependence2
2CompletedTreatmentAlcohol Dependence / Alcoholism1
2CompletedTreatmentAlcohol Dependence / Dependence, Cocaine2
2CompletedTreatmentAlcohol Use Disorder (AUD)1
2CompletedTreatmentAlcohol-Related Disorders / Alcoholism / Cocaine-Related Disorders2
2CompletedTreatmentAlcohol-Related Disorders / Cocaine-Related Disorders1
2CompletedTreatmentAlcoholism2
2CompletedTreatmentAlcoholism / HIV Disease1
2CompletedTreatmentAmphetamine-Related Disorders1
2CompletedTreatmentBMI >27 kg/m2 / BMI >30 kg/m2 / Nicotine Dependence1
2CompletedTreatmentBMI >30 kg/m21
2CompletedTreatmentBorderline Personality Disorder (BPD) / Dissociation1
2CompletedTreatmentCessation, Smoking / Smoking1
2CompletedTreatmentCocaine-Related Disorders1
2CompletedTreatmentCompulsive sexual behaviour1
2CompletedTreatmentCrohn's Disease (CD)1
2CompletedTreatmentCrohn's Disease (CD) / Inflammatory processes1
2CompletedTreatmentGulf War Illness1
2CompletedTreatmentHazardous Drinking / Smoking, Cigarette1
2CompletedTreatmentHeroin Dependence2
2CompletedTreatmentHeroin Dependence / Opioid-Related Disorders / Substance-Related Disorders1
2CompletedTreatmentKleptomania1
2CompletedTreatmentMajor Depressive Disorder (MDD) / Recurrences / Relapses / Unipolar Depression1
2CompletedTreatmentMalignant Gliomas1
2CompletedTreatmentMethamphetamine Dependence2
2CompletedTreatmentNicotine Dependence1
2CompletedTreatmentOpiate Dependence4
2CompletedTreatmentOpioid Dependence1
2CompletedTreatmentOpioid-Related Disorders1
2CompletedTreatmentPain, Chronic1
2CompletedTreatmentSmoking1
2CompletedTreatmentTrichotillomania1
2Not Yet RecruitingTreatmentPsoriatic Arthritis / Rheumatoid Arthritis / Synovitis of osteoarthritis1
2RecruitingNot AvailableAlcohol Drinking1
2RecruitingTreatmentAlcohol Use Disorder (AUD) / Nicotine Dependence1
2RecruitingTreatmentAlcohol Use Disorder (AUD) / PTSD1
2RecruitingTreatmentBinge Drinking1
2RecruitingTreatmentBinge Drinking / HIV Disease1
2RecruitingTreatmentPrescription Opiate/Medication Dependence1
2TerminatedTreatmentCancer, Breast1
2TerminatedTreatmentCarcinoma of the Prostate / Melanoma / Renal Cancers1
2TerminatedTreatmentObsessive-Compulsive Disorder (OCD)1
2Unknown StatusTreatmentCocaine Abuse / Cocaine-Related Disorders1
2Unknown StatusTreatmentOpioid-Dependence Among Adolescents1
2WithdrawnTreatmentCrohn's Disease (CD) / Inflammatory Bowel Diseases (IBD) / Ulcerative Colitis (UC)1
2WithdrawnTreatmentHuman Immunodeficiency Virus (HIV) Infections / Opiate Dependence1
2WithdrawnTreatmentOpioid-Related Disorders2
2WithdrawnTreatmentPyromania1
2, 3Active Not RecruitingTreatmentHeroin Dependence / Opioid-Related Disorders1
2, 3Active Not RecruitingTreatmentOpiate Dependence1
2, 3Active Not RecruitingTreatmentReduction in Heavy Drinking in Patients With HIV1
2, 3CompletedTreatmentAlcohol Dependence1
2, 3CompletedTreatmentDependence, Cocaine1
2, 3CompletedTreatmentHeroin Dependence / Opioid Dependence1
2, 3CompletedTreatmentOpiate Addiction1
2, 3CompletedTreatmentOpioid Dependence1
2, 3Enrolling by InvitationTreatmentBinge Eating Disorder (BED) / BMI >30 kg/m22
2, 3RecruitingTreatmentBinge Eating Disorder (BED) / BMI >30 kg/m21
2, 3RecruitingTreatmentDrug Dependence1
2, 3RecruitingTreatmentHuman Immunodeficiency Virus (HIV) / Opiate Dependence1
2, 3RecruitingTreatmentOpioid-use Disorder1
2, 3Unknown StatusTreatmentTobacco Use Disorders1
3Active Not RecruitingTreatmentOpiate Dependence1
3Active Not RecruitingTreatmentOpioid Dependence1
3CompletedNot AvailableWithdrawal Symptoms1
3CompletedTreatmentAlcohol Abuse / Alcohol Drinking / Alcohol-Related Disorders / Alcoholism1
3CompletedTreatmentAlcohol Dependence6
3CompletedTreatmentAlcohol Use Disorder (AUD) / Opioid Use Disorders1
3CompletedTreatmentAlcoholism5
3CompletedTreatmentAlcoholism / Dependence, Cocaine2
3CompletedTreatmentAlcoholism / Depression / PTSD1
3CompletedTreatmentAmphetamine Dependence1
3CompletedTreatmentAnalgesia / Low Back Pain (LBP) / Pain, Chronic1
3CompletedTreatmentGambling1
3CompletedTreatmentHeroin Dependence / Opiate Dependence1
3CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections1
3CompletedTreatmentMultiple Sclerosis (MS)1
3CompletedTreatmentOpiate Dependence3
3CompletedTreatmentPain1
3CompletedTreatmentPain, Chronic / Synovitis of osteoarthritis1
3CompletedTreatmentTobacco Use Disorders1
3RecruitingBasic ScienceAlcoholism1
3RecruitingTreatmentHIV Disease / Human Immunodeficiency Virus (HIV) Infections / Substance Abuse1
3RecruitingTreatmentOpioid Use Disorders2
3TerminatedTreatmentAlcoholism / Opiate Dependence1
3TerminatedTreatmentBMI >27 kg/m2 / BMI >30 kg/m21
3TerminatedTreatmentBorderline Personality Disorder (BPD)1
3Unknown StatusTreatmentAlcohol Abuse / Alcohol Dependence1
3Unknown StatusTreatmentMental Retardation / Self-Injurious Behavior1
4Active Not RecruitingTreatmentAlcohol Use Disorder (AUD) / HIV Disease1
4Active Not RecruitingTreatmentBMI >30 kg/m21
4CompletedBasic ScienceHeroin Dependence / Opioid-Related Disorders1
4CompletedBasic ScienceNeuroscience of Dreaming, Healthy1
4CompletedDiagnosticHealthy Volunteers1
4CompletedTreatmentAdhd / Stimulant-Induced Euphoria1
4CompletedTreatmentAlcohol Abuse / Alcohol-Related Disorders / Alcoholism / Mental Disorders / Schizophrenia1
4CompletedTreatmentAlcohol Consumption1
4CompletedTreatmentAlcohol Consumption / Alcohol-Induced Disorders / Alcoholic Intoxication / Alcoholism1
4CompletedTreatmentAlcohol Dependence5
4CompletedTreatmentAlcohol Dependence / Alcohol Drinking / Alcoholism1
4CompletedTreatmentAlcohol Dependence / Alcoholism1
4CompletedTreatmentAlcohol Dependence / Alcoholism / Depression1
4CompletedTreatmentAlcohol Dependence / Alcoholism / Post-Traumatic Stress Disorder (PTSD)1
4CompletedTreatmentAlcohol Dependence / Bipolar Disorder (BD)1
4CompletedTreatmentAlcohol Dependence / Bipolar Disorder (BD) / Schizoaffective Disorders / Schizophrenia1
4CompletedTreatmentAlcoholism11
4CompletedTreatmentAlcoholism / Depression2
4CompletedTreatmentAlcoholism / Eating Disorder1
4CompletedTreatmentAlcoholism / Smoking2
4CompletedTreatmentAttention Deficit Hyperactivity Disorder (ADHD)1
4CompletedTreatmentImpulse Control Disorder / Parkinson's Disease (PD)1
4CompletedTreatmentOpioid Dependence1
4CompletedTreatmentOpioid Use Disorders1
4CompletedTreatmentSubstance-Related Disorders1
4Enrolling by InvitationTreatmentAlcohol Dependence / Alcohol Use Disorder (AUD) / Heavy Drinking1
4Enrolling by InvitationTreatmentHeroin Dependence / Opioid Dependence1
4Not Yet RecruitingNot AvailableOpioid-Related Disorders1
4Not Yet RecruitingHealth Services ResearchAddictions / Hepatitis / HIV/AIDS / Opioid Dependence / Tuberculosis1
4Not Yet RecruitingTreatmentCigarette-smoking / Obese / Schizophrenia1
4Not Yet RecruitingTreatmentSelf Mutilation / Self-Injurious Behavior1
4RecruitingTreatmentAlcohol Dependence1
4RecruitingTreatmentAlcohol Dependence / Alcohol Use Disorder (AUD)1
4RecruitingTreatmentDrug Dependence1
4RecruitingTreatmentFibromyalgia1
4RecruitingTreatmentHeroin Dependence / Opioid-Related Disorders1
4TerminatedHealth Services ResearchAlcohol Dependence1
4TerminatedSupportive CareChronic Diseases / Pain1
4TerminatedTreatmentAdhd / Attention Deficit Hyperactivity Disorder (ADHD)1
4TerminatedTreatmentAlcohol Dependence1
4TerminatedTreatmentBMI >30 kg/m2 / Cardiovascular Diseases1
4Unknown StatusTreatmentAlcoholism1
4WithdrawnTreatmentHeavy Alcoholic Consumption / Human Immunodeficiency Virus (HIV) Infections1
4WithdrawnTreatmentOpiate Addiction1
Not AvailableActive Not RecruitingTreatmentBipolar Disorder (BD) / Schizoaffective Disorders / Schizophrenia / Schizophreniform Disorder / Severe Major Depression With Psychotic Features1
Not AvailableCompletedNot AvailableAddictions1
Not AvailableCompletedNot AvailableFood Addiction1
Not AvailableCompletedNot AvailableHIV Disease / Methamphetamine Abuse1
Not AvailableCompletedNot AvailableHealthy Adults1
Not AvailableCompletedNot AvailableObsessive Compulsive Disorder (OCD)1
Not AvailableCompletedBasic ScienceBioavailability1
Not AvailableCompletedBasic SciencePsychology, Social1
Not AvailableCompletedTreatmentAids / Alcohol Dependence / Hazardous Drinking / Human Immunodeficiency Virus (HIV) / Problem Drinking1
Not AvailableCompletedTreatmentAlcohol Use Disorders (AUD) / Tuberculosis1
Not AvailableCompletedTreatmentBMI >30 kg/m2 / Schizoaffective Disorders / Schizophrenia1
Not AvailableCompletedTreatmentBinge Eating Disorder (BED)1
Not AvailableCompletedTreatmentConcurrent Alcohol Dependence and Pathological Gambling1
Not AvailableCompletedTreatmentFibromyalgia / Persian Gulf Syndrome1
Not AvailableCompletedTreatmentHypoglycemia1
Not AvailableCompletedTreatmentOpiate Addiction1
Not AvailableCompletedTreatmentOpioid Dependence1
Not AvailableCompletedTreatmentSmoking1
Not AvailableCompletedTreatmentSocial Drinker1
Not AvailableRecruitingNot AvailableAlcohol Dependence / Cocaine Abuse / Dependence, Cocaine / Opiate Dependence / Substance Abuse1
Not AvailableRecruitingBasic ScienceAlcohol Dependence / Attention Deficit Hyperactivity Disorder (ADHD) / Attention Deficit Hyperactivity Disorder and Alcohol Dependence / Healthy Volunteers1
Not AvailableRecruitingBasic ScienceSocial Acceptance1
Not AvailableSuspendedOtherFatigue Syndrome, Chronic1
Not AvailableUnknown StatusNot AvailableFibromyalgia1
Not AvailableUnknown StatusBasic SciencePain1
Not AvailableUnknown StatusTreatmentAlcohol-dependence1
Not AvailableWithdrawnBasic ScienceFacial Pain / Temporomandibular Disorders1
Not AvailableWithdrawnTreatmentFibromyalgia1
Pharmacoeconomics
Manufacturers
  • Alkermes inc
  • Actavis totowa llc
  • Barr laboratories inc
  • Mallinckrodt inc
  • Sandoz inc
  • Duramed pharmaceuticals inc
Packagers
Dosage forms
FormRouteStrength
Tablet, film coated, extended releaseOral
Tablet, extended releaseOral
Capsule, extended releaseOral
Tablet, film coatedOral50 mg/1
TabletOral50 mg
Kit
Prices
Unit descriptionCostUnit
Vivitrol injectable suspension960.0USD each
ReVia 30 50 mg tablet Bottle291.73USD bottle
Naltrexone hcl powder172.54USD g
Naltrexone powder69.0USD g
Revia 50 mg tablet9.35USD tablet
Naltrexone 50 mg tablet4.57USD tablet
Naltrexone HCl 50 mg tablet4.45USD tablet
Depade 50 mg tablet4.28USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5792477 No1997-05-022017-05-02Us
US5916598 No1997-05-022017-05-02Us
US6194006 No1998-12-302018-12-30Us
US6264987 No2000-05-192020-05-19Us
US6331317 No1999-11-122019-11-12Us
US6379703 No1998-12-302018-12-30Us
US6379704 No2000-05-192020-05-19Us
US6395304 No1999-11-122019-11-12Us
US6403114 No1997-05-022017-05-02Us
US6495164 No2000-05-252020-05-25Us
US6495166 No1999-11-122019-11-12Us
US6534092 No2000-05-192020-05-19Us
US6537586 No1999-11-122019-11-12Us
US6596316 No1998-12-302018-12-30Us
US6667061 No2000-05-252020-05-25Us
US6713090 No1999-11-122019-11-12Us
US6939033 No1999-11-122019-11-12Us
US7375111 No2005-03-262025-03-26Us
US7462626 No2004-07-202024-07-20Us
US7682633 No2007-06-192027-06-19Us
US7682634 No2007-06-192027-06-19Us
US7799345 No2000-05-252020-05-25Us
US7815934 No2007-12-122027-12-12Us
US7919499 No2009-10-152029-10-15Us
US8088786 No2009-02-032029-02-03Us
US8158156 No2007-06-192027-06-19Us
US8318788 No2007-11-082027-11-08Us
US8623418 No2009-11-072029-11-07Us
US8685443 No2005-07-032025-07-03Us
US8685444 No2005-07-032025-07-03Us
US8722085 No2007-11-082027-11-08Us
US8815889 No2004-07-202024-07-20Us
US8846104 No2007-06-192027-06-19Us
US8877247 No2007-06-192027-06-19Us
US8916195 No2010-02-022030-02-02Us
US9107837 No2007-06-042027-06-04Us
US9125868 No2007-11-082027-11-08Us
US9248123 No2012-01-132032-01-13Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point168-170 °CPhysProp
water solubility100 mg/mL (as hydrochloride salt)Not Available
logP1.92HANSCH,C ET AL. (1995)
Predicted Properties
PropertyValueSource
Water Solubility3.07 mg/mLALOGPS
logP2.07ALOGPS
logP1.36ChemAxon
logS-2ALOGPS
pKa (Strongest Acidic)7.39ChemAxon
pKa (Strongest Basic)11.54ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area70 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity91.5 m3·mol-1ChemAxon
Polarizability35.97 Å3ChemAxon
Number of Rings6ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9769
Blood Brain Barrier+0.9671
Caco-2 permeable+0.7471
P-glycoprotein substrateSubstrate0.8685
P-glycoprotein inhibitor INon-inhibitor0.8867
P-glycoprotein inhibitor IINon-inhibitor0.8718
Renal organic cation transporterNon-inhibitor0.5189
CYP450 2C9 substrateNon-substrate0.8336
CYP450 2D6 substrateSubstrate0.5925
CYP450 3A4 substrateSubstrate0.5981
CYP450 1A2 substrateInhibitor0.6656
CYP450 2C9 inhibitorNon-inhibitor0.9355
CYP450 2D6 inhibitorNon-inhibitor0.5686
CYP450 2C19 inhibitorNon-inhibitor0.9354
CYP450 3A4 inhibitorNon-inhibitor0.8993
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9483
Ames testNon AMES toxic0.6324
CarcinogenicityNon-carcinogens0.96
BiodegradationNot ready biodegradable0.9939
Rat acute toxicity2.7174 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.861
hERG inhibition (predictor II)Non-inhibitor0.8446
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-ITFT , positivesplash10-00di-0009000000-e30316dd5784a7100d38View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-ITFT , positivesplash10-0006-0009000000-2218214724e56047d52bView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-ITFT , positivesplash10-0006-0009000000-bb047c719f3429eb4410View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-ITFT , positivesplash10-00di-0049000000-de9a717563978f22f02fView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-ITFT , positivesplash10-00xr-0191000000-d2f2ff1e4eb93db46b5eView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-ITFT , positivesplash10-03di-1390000000-091705f6f42bc0f1c209View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-ITFT , positivesplash10-03di-1890000000-148c5608ef92c1dcaac4View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-ITFT , positivesplash10-0006-0009000000-6df03abdbdb7461f2945View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-ITFT , positivesplash10-0006-0009000000-059b1dffee7ef15b9e95View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-ITFT , positivesplash10-00di-0049000000-a20ede951b350fa97a31View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-ITFT , positivesplash10-00xr-0191000000-8a66ac92b4a1eadcc405View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-ITFT , positivesplash10-03di-1490000000-0cfb621f77295ff438f2View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-ITFT , positivesplash10-03di-1980000000-63edda852273619df16cView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-ITFT , positivesplash10-00di-0009000000-59ab0ef68d6e13a7d085View in MoNA
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenanthrenes and derivatives. These are polycyclic compounds containing a phenanthrene moiety, which is a tricyclic aromatic compound with three non-linearly fused benzene.
KingdomOrganic compounds
Super ClassBenzenoids
ClassPhenanthrenes and derivatives
Sub ClassNot Available
Direct ParentPhenanthrenes and derivatives
Alternative Parents
Substituents
  • Phenanthrene
  • Isoquinolone
  • Tetralin
  • Coumaran
  • 1-hydroxy-2-unsubstituted benzenoid
  • Alkyl aryl ether
  • Aralkylamine
  • Piperidine
  • Cyclic alcohol
  • Tertiary alcohol
  • 1,2-aminoalcohol
  • Ketone
  • Tertiary aliphatic amine
  • Tertiary amine
  • Ether
  • Oxacycle
  • Azacycle
  • Organoheterocyclic compound
  • Organonitrogen compound
  • Hydrocarbon derivative
  • Organic oxide
  • Organic nitrogen compound
  • Organopnictogen compound
  • Carbonyl group
  • Organooxygen compound
  • Alcohol
  • Organic oxygen compound
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Voltage-gated calcium channel activity
Specific Function:
Receptor for endogenous opioids such as beta-endorphin and endomorphin. Receptor for natural and synthetic opioids including morphine, heroin, DAMGO, fentanyl, etorphine, buprenorphin and methadone. Agonist binding to the receptor induces coupling to an inactive GDP-bound heterotrimeric G-protein complex and subsequent exchange of GDP for GTP in the G-protein alpha subunit leading to dissociati...
Gene Name:
OPRM1
Uniprot ID:
P35372
Molecular Weight:
44778.855 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Kato H: [Pharmacological effects of a mu-opioid receptor antagonist naltrexone on alcohol dependence]. Nihon Arukoru Yakubutsu Igakkai Zasshi. 2008 Oct;43(5):697-704. [PubMed:19068776 ]
  3. Helm S, Trescot AM, Colson J, Sehgal N, Silverman S: Opioid antagonists, partial agonists, and agonists/antagonists: the role of office-based detoxification. Pain Physician. 2008 Mar-Apr;11(2):225-35. [PubMed:18354714 ]
  4. Goodman AJ, Le Bourdonnec B, Dolle RE: Mu opioid receptor antagonists: recent developments. ChemMedChem. 2007 Nov;2(11):1552-70. [PubMed:17918759 ]
  5. Barrios de Tomasi E, Juarez-Gonzalez J: [Opioid antagonists and alcohol consumption]. Rev Neurol. 2007 Aug 1-15;45(3):155-62. [PubMed:17661275 ]
  6. Weerts EM, Kim YK, Wand GS, Dannals RF, Lee JS, Frost JJ, McCaul ME: Differences in delta- and mu-opioid receptor blockade measured by positron emission tomography in naltrexone-treated recently abstinent alcohol-dependent subjects. Neuropsychopharmacology. 2008 Feb;33(3):653-65. Epub 2007 May 9. [PubMed:17487229 ]
  7. Herz A: Opioid reward mechanisms: a key role in drug abuse? Can J Physiol Pharmacol. 1998 Mar;76(3):252-8. [PubMed:9673788 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Opioid receptor activity
Specific Function:
G-protein coupled opioid receptor that functions as receptor for endogenous alpha-neoendorphins and dynorphins, but has low affinity for beta-endorphins. Also functions as receptor for various synthetic opioids and for the psychoactive diterpene salvinorin A. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates th...
Gene Name:
OPRK1
Uniprot ID:
P41145
Molecular Weight:
42644.665 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Helm S, Trescot AM, Colson J, Sehgal N, Silverman S: Opioid antagonists, partial agonists, and agonists/antagonists: the role of office-based detoxification. Pain Physician. 2008 Mar-Apr;11(2):225-35. [PubMed:18354714 ]
  3. Herz A: Endogenous opioid systems and alcohol addiction. Psychopharmacology (Berl). 1997 Jan;129(2):99-111. [PubMed:9040115 ]
  4. Barrios de Tomasi E, Juarez-Gonzalez J: [Opioid antagonists and alcohol consumption]. Rev Neurol. 2007 Aug 1-15;45(3):155-62. [PubMed:17661275 ]
  5. Wee S, Orio L, Ghirmai S, Cashman JR, Koob GF: Inhibition of kappa opioid receptors attenuated increased cocaine intake in rats with extended access to cocaine. Psychopharmacology (Berl). 2009 Sep;205(4):565-75. doi: 10.1007/s00213-009-1563-y. Epub 2009 May 30. [PubMed:19484223 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Opioid receptor activity
Specific Function:
G-protein coupled receptor that functions as receptor for endogenous enkephalins and for a subset of other opioids. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling leads to the inhibition of adenylate cyclase activity. Inhibits neurot...
Gene Name:
OPRD1
Uniprot ID:
P41143
Molecular Weight:
40368.235 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Roy S, Guo X, Kelschenbach J, Liu Y, Loh HH: In vivo activation of a mutant mu-opioid receptor by naltrexone produces a potent analgesic effect but no tolerance: role of mu-receptor activation and delta-receptor blockade in morphine tolerance. J Neurosci. 2005 Mar 23;25(12):3229-33. [PubMed:15788780 ]
  3. Barrios de Tomasi E, Juarez-Gonzalez J: [Opioid antagonists and alcohol consumption]. Rev Neurol. 2007 Aug 1-15;45(3):155-62. [PubMed:17661275 ]
  4. Weerts EM, Kim YK, Wand GS, Dannals RF, Lee JS, Frost JJ, McCaul ME: Differences in delta- and mu-opioid receptor blockade measured by positron emission tomography in naltrexone-treated recently abstinent alcohol-dependent subjects. Neuropsychopharmacology. 2008 Feb;33(3):653-65. Epub 2007 May 9. [PubMed:17487229 ]
  5. Herz A: Opioid reward mechanisms: a key role in drug abuse? Can J Physiol Pharmacol. 1998 Mar;76(3):252-8. [PubMed:9673788 ]
  6. Herz A: Endogenous opioid systems and alcohol addiction. Psychopharmacology (Berl). 1997 Jan;129(2):99-111. [PubMed:9040115 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Not Available
Specific Function:
Not Available
Gene Name:
SIGMAR1
Uniprot ID:
Q5T1J1
Molecular Weight:
14852.655 Da
References
  1. Helm S, Trescot AM, Colson J, Sehgal N, Silverman S: Opioid antagonists, partial agonists, and agonists/antagonists: the role of office-based detoxification. Pain Physician. 2008 Mar-Apr;11(2):225-35. [PubMed:18354714 ]
  2. Wee S, Orio L, Ghirmai S, Cashman JR, Koob GF: Inhibition of kappa opioid receptors attenuated increased cocaine intake in rats with extended access to cocaine. Psychopharmacology (Berl). 2009 Sep;205(4):565-75. doi: 10.1007/s00213-009-1563-y. Epub 2009 May 30. [PubMed:19484223 ]
  3. Herz A: Endogenous opioid systems and alcohol addiction. Psychopharmacology (Berl). 1997 Jan;129(2):99-111. [PubMed:9040115 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid binding
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform glucuronidates bilirubin IX-alpha to form both the IX-alpha-C8 and IX-alpha-C12 monoconjugates and diconjugate. Is also able to catalyze the glucuronidation of 17beta-estradiol, 17alpha-ethinylestradiol, 1-hydroxypyrene, 4-methylumbelliferone, 1-naph...
Gene Name:
UGT1A1
Uniprot ID:
P22309
Molecular Weight:
59590.91 Da
References
  1. Antonilli L, Brusadin V, Milella MS, Sobrero F, Badiani A, Nencini P: In vivo chronic exposure to heroin or naltrexone selectively inhibits liver microsome formation of estradiol-3-glucuronide in the rat. Biochem Pharmacol. 2008 Sep 1;76(5):672-9. doi: 10.1016/j.bcp.2008.06.011. Epub 2008 Jul 1. [PubMed:18639530 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Mahar Doan KM, Humphreys JE, Webster LO, Wring SA, Shampine LJ, Serabjit-Singh CJ, Adkison KK, Polli JW: Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther. 2002 Dec;303(3):1029-37. [PubMed:12438524 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on April 28, 2017 04:57